Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study Meeting Abstract
| Authors: | Beckermann, K.; Choueiri, T. K.; Motzer, R. J.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P. C.; McKay, R. R.; Chehrazi-Raffle, A.; Hammers, H. J.; Heng, D. Y. C.; Braendle, E. E.; Lebedinsky, C.; Jin, B.; Albiges, L.; McGregor, B. A. |
| Abstract Title: | Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study |
| Meeting Title: | 2025 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2025 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-10 |
| Language: | English |
| ACCESSION: | WOS:001454809900048 |
| DOI: | 10.1200/JCO.2025.43.5_suppl.459 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 459 -- Source: Wos |
